3月17日，國務院聯防聯控機制就藥物疫苗和檢測試劑研發攻關最新情況舉行發布會。會上，中國工程院院士王軍志表示，我國新冠疫苗研發進展目前總體上處於國際先進行列，不會慢於國外。
Employees check novel coronavirus testing kits at the production facility of a biotech company in Taizhou, Jiangsu province. [Photo by Tang Dehong/For China Daily]
Chinese scientists have been racing to develop COVID-19 vaccines by five approaches, namely inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines, and vaccines using attenuated influenza virus as vectors, said Wang Junzhi, an academician with the Chinese Academy of Engineering.中國工程院院士王軍志說，目前，我國正按照5種技術路線開展新冠疫苗緊急研製，包括滅活疫苗、基因工程重組亞單位疫苗、腺病毒載體疫苗、核酸疫苗以及減毒流感病毒載體疫苗。
王軍志表示，截至目前為止，五大技術方向總體進展順利。
So far, most teams are expected to complete preclinical research in April and some are moving forward faster, said Wang.大部分研發團隊4月份都能完成臨床前研究，有的團隊進展更快。
Some research team has been enrolling volunteers and applied for clinical trials with the National Medical Products Administration, he added.有些研發團隊已向國家藥監局遞交臨床試驗申請材料，並且已經開展招募志願者等相關工作。
In general, China's vaccine development against COVID-19 is among the world's front-runners.我國新冠疫苗研發進展目前總體上處於國際先進行列。
教育部科技司司長雷朝滋表示，教育部從春節就開始動員有研究優勢的廈門大學、四川大學、清華大學、北京大學等高校科研團隊，協同科研院所和相關企業加快開展新冠病毒疫苗的科研公關。
Lei said that the flu viral vector-based vaccine is currently under animal tests for safety and efficacy tests and scheduled to apply for the clinical trial by the end of April.雷朝滋介紹道，流感病毒載體疫苗目前正在進行實驗動物的有效性和安全性研究，預計4月底申請臨床試驗。
在3月16日舉行的上海疫情防控新聞發布會上，上海市衛健委透露，針對新冠病毒疫苗研發，上海已取得積極進展。
China would begin testing its messenger ribonucleic acid vaccine, or mRNA vaccine, on primates to evaluate its safety and efficacy, and hopefully the vaccine could enter clinical trials by mid-April.我國mRNA（信使RNA）疫苗已啟動靈長類動物毒理和藥效預實驗，預計4月中旬臨床試驗。
【相關詞彙】
臨床試驗 clinical trial
臨床前研究 preclinical research
動物試驗 animal test
毒性試驗 toxicology test
有效性和安全性研究 safety and efficacy research
免疫系統 immune system
參考來源：新華網、人民網
（中國日報網英語點津 Helen）
來源：中國日報網